362 First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers

R.M. Wenham; Shahneen Sandhu; George Wilding; Linda Sun; Carlo Toniatti; Mark Stroh; Catherine L. Carpenter; Johann S. de Bono; Richard D. Baird; William R. Schelman

doi:10.1016/s1359-6349(10)72069-3

Article2011

First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).

William R. Schelman, Shahneen Sandhu, Víctor Moreno, G. Wilding, Long Sun, Carlo Toniatti, Mark Stroh, N. Kreischer, Celia L. Carpenter, L. Rhoda Molife, S. B. Kaye, Johann S. de Bono, R.M. Wenham

Article2011

First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers

Robert M. Wenham, George Wilding, Richard D. Baird, Linda Sun, Carlo Toniatti, Mark Stroh, Catherine L. Carpenter, Johann S. de Bono, Shahneen Sandhu, William R. Schelman

Article2012

352 Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients

Shahneen Sandhu, G. Wilding, William R. Schelman, Aurelius Omlin, N. Kreischer, Catherine L. Carpenter, Raffaele Iannone, Stuart Kaye, Johann S. de Bono, R.M. Wenham

Article2013

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

Shahneen Sandhu, William R. Schelman, George Wilding, Víctor Moreno, Richard D. Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Förster, Aurelius Omlin, N. Kreischer, Khin Thway, Heidrun Gevensleben, Linda Sun, John W. Loughney, Manash Chatterjee, Carlo Toniatti, Christopher L. Carpenter, Robert Iannone, Stan B. Kaye, Johann S. de Bono, Robert M. Wenham

Article2015

Antitumour Activity of the Poly(Adp-Ribose) Polymerase (Parp) Inhibitor Olaparib in Unselected Sporadic Castration Resistant Prostate Cancer (Crpc) in the Toparp Trial

Shahneen Sandhu, Joaquı́n Mateo, Susana Miranda, Suzanne Carreira, Shreyans K. Jain, Christy Ralph, Andrew Protheroe, S. Perwez Hussain, Robin L. Jones, Tony Elliot, Ursula McGovern, Alexa Gillman, Claire Paulding, Helen Mossop, Núria Porta, Diletta Bianchini, Zafeiris Zafeiriou, Gunther Boysen, DN Rodrigues, Penny Flohr, George Seed, ,

362 First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers

Discussion(0)

Related publications

First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).

First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers

352 Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

Antitumour Activity of the Poly(Adp-Ribose) Polymerase (Parp) Inhibitor Olaparib in Unselected Sporadic Castration Resistant Prostate Cancer (Crpc) in the Toparp Trial